Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IND Safety Reports: Industry Praises FDA’s Move Towards Less Unblinding, But Wants More Flexibility

Executive Summary

Sponsors are pleased with agency’s embrace of the ‘trigger’ approach to unblinding for safety reporting in new guidance but continue to want additional ways to keep the blind. Industry also raised concerns that parts of the guidance contradict international regulators.

You may also be interested in...



US FDA Is No Longer ‘Getting Crap’ From Sponsors In IND Safety Reports, Temple Says

FDA’s Robert Temple says he is gratified by the way companies have implemented the agency’s guidance on IND safety reporting. Merck, AbbVie and Janssen representatives discuss issues with unblinding data and the value of an aggregate analysis at DIA’s annual meeting.

IND Safety Analysis Requires Broader Unblinding Of Reports, US FDA Advises

A draft guidance from the US Food and Drug Administration is recommending that pharmaceutical sponsors develop safety assessment committees that would review safety information in a drug development program and determine what information must be reported in an investigational new drug (IND) safety report.

Pfizer COVID Shot: Unanimous Vote Obscures Reservations About Vaccinating All Children 5-11

Many of US FDA's outside vaccine advisors wanted to wait for more data before widespread inoculations of kids 5-11, but felt some high-risk populations should get access to vaccine right away. They urged CDC to provide additional guidance on which children should be targeted.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel